Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B]...

Details Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B]... Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B]...

2011-05-31

2011-05-31

Hui, San-ming (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S341000, C514S395000, C546S118000, C548S314700

Reexamination Certificate

active

07951819

ABSTRACT:
The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5 b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.

REFERENCES:
patent: 4666828 (1987-05-01), Gusella
patent: 4683202 (1987-07-01), Mullis
patent: 4801531 (1989-01-01), Frossard
patent: 5192659 (1993-03-01), Simons
patent: 5272057 (1993-12-01), Smulson
patent: 5521073 (1996-05-01), Davis et al.
patent: 5877020 (1999-03-01), Alitalo
patent: 5879672 (1999-03-01), Davis et al.
patent: 5882864 (1999-03-01), An et al.
patent: 6030831 (2000-02-01), Godowski et al.
patent: 6218529 (2001-04-01), An et al.
patent: 6258809 (2001-07-01), Parthasarathi et al.
patent: 6492529 (2002-12-01), Kapadia et al.
patent: 2004/0082583 (2004-04-01), Cheung et al.
patent: 56065863 (1981-06-01), None
patent: 57038777 (1982-03-01), None
patent: WO 99/16438 (1999-04-01), None
patent: WO 99/21859 (1999-05-01), None
patent: WO 01/36383 (2001-05-01), None
patent: WO 01/46196 (2001-06-01), None
patent: WO 03/056036 (2003-07-01), None
patent: WO 2004/014300 (2004-02-01), None
patent: WO 2006/003378 (2006-01-01), None
patent: WO 2006/024834 (2006-03-01), None
patent: WO 2006/043090 (2006-04-01), None
Adams, R.H. et al, 1999, “Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis”, Genes Dev., vol. 13, pp. 295-306.
Ananthanarayanan, C., et al, 1988, “Reaction of azides in presence of aluminium chloride”, Indian Journal of Chemistry, Section B, vol. 27B, pp. 156-157.
Angerer, L.M., et al, 1987, “Demonstration of tissue-specific gene expression by in situ hybridization”, Methods in Enzymology, vol. 152, pp. 649-661.
Auvray, P., et al, 1988, “Preparation and nucleophilic substitution of (E)-1-bromo-2-phenylsulfonyl-2-alkenes and 3-acetoxy-2-phenylsulfonyl-1-alkenes”, Tetrahedron, vol. 44, pp. 6095-6106.
Avenoza, A., et al, 1995, “New efficient synthesis of 4-amino-3-arylphenols”, Synthesis, pp. 671-674.
Ballesteros, P., et al, 1987, “Study of the catalytic properties of tris (3,6-dioxaheptyl) amine (TDA-1) in heteroaromatic nucleophilic substitution of chloropyridines and their N-oxides”, Tetrahedron, vol. 43, pp. 2557-2564.
Bhatt, D.J., et al, 1980, “Preparation of N′-2-phenyl-4-quinolinoyl-N3-aryl thioureas”, J. Instit. Chem. (India), vol. 52, pp. 113-114.
Bianchi, M., et al, 1981, “Compounds with antiulcer and antisecretory activity”, Eur. J. Med. Chem., vol. 16, pp. 321-326.
Borthakur, N., et al, 1995, “New direct synthesis of thioamides from carboxylic acids”, Tetrahedron Letters, vol. 36, pp. 6745-6746.
Broekhof, N., et al, 1981, “Novel applications of α-aminosubstituted diphenylphosphine oxides. The conversion of aldehydes into α-aminomethylketones”, Tetrahedron Letters, vol. 22, pp. 2799-2802.
Brooks, P.C., et al, 1994, “Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels”, Cell, vol. 79, pp. 1157-1164.
Brose, M.S., et al, 2002, “BRAFandRASmutations in human lung cancer and melanoma”, Cancer Research, vol. 62, pp. 6997-7000.
Bruckner, K., et al, 1997, “Tyrosine phosphorylation of transmembrane ligands for Eph receptors”, Science, vol. 275, pp. 1640-1643.
Bruder, J.T., et al, 1992, “Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promotors requires Raf-1 kinase”, Genes & Development, vol. 6, pp. 545-556.
Cantrell, D.A., 2003, “GTPases and T cell activation”, Immunological Reviews, vol. 192, pp. 122-130.
Chan, A.C., et al, 1996, “Regulation of antigen receptor signal tgransdu8ction by protein tyrosine kinases”, Current Opin. Immunol., vol. 8, pp. 394-401.
Clare, B.W., et al, 2001, “Protease inhibitors: synthesis of a series of bacterial collagenase inhibitors of the sulfonyl amino acyl hydroxamate type”, J. Med. Chem., vol. 44, pp. 2253-2258.
Cohen, Y., et al, 2003, “Lack of BRAF mutation in primary uveal melanoma”, Invest. Ophthalmol. Vis. Sci., vol. 44, pp. 2876-2878.
Colville-Nash, P.R., et al, 1992, “Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications”, Annals of the Rheum. Dis., vol. 51, pp. 919-925.
Comins, D.L., et al, 1994, “Grignard addition to 1-acyl salts of chiral 4-alkoxypyridines. A new enantioselective preparation of 2-alkyl-2,3-dihydro-4-pyridones”, Tetrahedron Letters, vol. 35, pp. 7343-7346.
Cooper, J.A., 1994, “Membrane-associated tyrosine kinases as molecular switches”, Sem. Cell Biology, vol. 5, pp. 377-387.
Correia, J., 1978, “Reaction of phenylglyoxal with aniline under acidic conditions”, J. Org. Chem., vol. 43, pp. 3394-3396.
Courtneidge, S.A., et al, 1993, “The Src family of protein tyrosine kinases: regulation and functions”, Development 1993 Supplement, pp. 57-64.
Cowley, S., et al, 1994, “Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells”, Cell, vol. 77, pp. 841-852.
Davies, H., et al, 2002, “Mutations of theBRAFgene in human cancer”, Nature, vol. 417, pp. 949-954.
Davis, S., et al, 1996, “Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning”, Cell, vol. 87, pp. 1161-1169.
Denekamp, J., 1993, “Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy”, British Journal of Radiology, vol. 66, pp. 181-196.
Dickson, B., et al, 1992, “Raf functions downstream of Ras1 in the sevenless signal transduction pathway”, Nature, vol. 360, pp. 600-603.
Dubois, G.E., 1980, “Amination of aryl sufamate esters. A convenient general synthesis of aliphatic sulfamides”, Journal of Organic Chemistry, vol. 45, pp. 5373-5375.
Fidler, I.J., et al, 1994, “The implications of angiogenesis for the biology and therapy of cancer metastasis”, Cell, vol. 79, pp. 185-188.
Folkman, J., et al, 1992, “Angiogensis”, Journal of Biol. Chem., vol. 267, pp. 10931-10934.
Folkman, J., 1992, “The role of angiogenesis in tumor growth”, Cancer Biology, vol. 3, pp. 65-71.
Folkman, J., et al, 1995, “Angiogenesis in cancer, vascular, rheumatoid and other disease”, Nature Medicine, vol. 1, pp. 27-31.
Folkman, J., 1997, “Angiogenesis and angiogenesis inhibition: an overview”, Regulation of Angiogenesis, EXS, vol. 79, pp. 1-8.
Fourrey, J-L.,1987, “Preparation of stable 1,4-dihydropyrazines”, J. Chem. Soc., Perkins Transactions 1: Org. & Bio. Chem., vol. 8, pp. 1841-1843.
Friedlander, et al, 1995, “Definition of two angiogenic pathways by distinct αv integrins”, Science, vol. 270, pp. 1500-1502.
Gale, N. et al, 1999, “Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development”, Genes Dev., vol. 13, pp. 1055-1066.
Galons, H., et al, 1981, “Cyclisation indolique selon Bischler en presence d'acides de Lewis”, J. Heterocyclic Chemistry, vol. 18, pp. 561-563 (in French, with partial English language translation).
Genot, E., et al, 2000, “Ras regulation and functio

Affiliated with

Also associated with

Rating

Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B]... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B]..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B]... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2683584